Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.

Bharathy N, Berlow NE, Wang E, Abraham J, Settelmeyer TP, Hooper JE, Svalina MN, Bajwa Z, Goros MW, Hernandez BS, Wolff JE, Pal R, Davies AM, Ashok A, Bushby D, Mancini M, Noakes C, Goodwin NC, Ordentlich P, Keck J, Hawkins DS, Rudzinski ER, Mansoor A, Perkins TJ, Vakoc CR, Michalek JE, Keller C.

Skelet Muscle. 2019 May 21;9(1):12. doi: 10.1186/s13395-019-0198-x.

2.

The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma.

Bharathy N, Berlow NE, Wang E, Abraham J, Settelmeyer TP, Hooper JE, Svalina MN, Ishikawa Y, Zientek K, Bajwa Z, Goros MW, Hernandez BS, Wolff JE, Rudek MA, Xu L, Anders NM, Pal R, Harrold AP, Davies AM, Ashok A, Bushby D, Mancini M, Noakes C, Goodwin NC, Ordentlich P, Keck J, Hawkins DS, Rudzinski ER, Chatterjee B, Bächinger HP, Barr FG, Liddle J, Garcia BA, Mansoor A, Perkins TJ, Vakoc CR, Michalek JE, Keller C.

Sci Signal. 2018 Nov 20;11(557). pii: eaau7632. doi: 10.1126/scisignal.aau7632.

3.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ.

Cancer Res. 2017 Nov 1;77(21):e62-e66. doi: 10.1158/0008-5472.CAN-17-0582.

4.

Genetic background influences susceptibility to chemotherapy-induced hematotoxicity.

Gatti DM, Weber SN, Goodwin NC, Lammert F, Churchill GA.

Pharmacogenomics J. 2018 Apr;18(2):319-330. doi: 10.1038/tpj.2017.23. Epub 2017 Jun 13.

5.

LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice.

Powell DR, Smith MG, Doree DD, Harris AL, Greer J, DaCosta CM, Thompson A, Jeter-Jones S, Xiong W, Carson KG, Goodwin NC, Harrison BA, Rawlins DB, Strobel ED, Gopinathan S, Wilson A, Mseeh F, Zambrowicz B, Ding ZM.

J Pharmacol Exp Ther. 2017 Jul;362(1):85-97. doi: 10.1124/jpet.117.240820. Epub 2017 Apr 25.

PMID:
28442582
6.

Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes.

Goodwin NC, Ding ZM, Harrison BA, Strobel ED, Harris AL, Smith M, Thompson AY, Xiong W, Mseeh F, Bruce DJ, Diaz D, Gopinathan S, Li L, O'Neill E, Thiel M, Wilson AG, Carson KG, Powell DR, Rawlins DB.

J Med Chem. 2017 Jan 26;60(2):710-721. doi: 10.1021/acs.jmedchem.6b01541. Epub 2017 Jan 17.

PMID:
28045524
7.

Ischemic preconditioning, retinal neuroprotection and histone deacetylase activities.

Fan J, Alsarraf O, Chou CJ, Yates PW, Goodwin NC, Rice DS, Crosson CE.

Exp Eye Res. 2016 May;146:269-75. doi: 10.1016/j.exer.2016.03.026. Epub 2016 Apr 6.

8.

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.

Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, DeVries PJ, Cheng D, Meulbroek JA, Buchanan FG, McKay LM, Goodwin NC, Reilly EB.

Mol Cancer Ther. 2016 Apr;15(4):661-9. doi: 10.1158/1535-7163.MCT-15-0901. Epub 2016 Feb 4.

9.

A Patient-Derived Xenograft Model of Parameningeal Embryonal Rhabdomyosarcoma for Preclinical Studies.

Hooper JE, Cantor EL, Ehlen MS, Banerjee A, Malempati S, Stenzel P, Woltjer RL, Gandour-Edwards R, Goodwin NC, Yang Y, Kaur P, Bult CJ, Airhart SD, Keller C.

Sarcoma. 2015;2015:826124. doi: 10.1155/2015/826124. Epub 2015 Nov 30.

10.

LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2.

Powell DR, Smith MG, Doree DD, Harris AL, Xiong WW, Mseeh F, Wilson A, Gopinathan S, Diaz D, Goodwin NC, Harrison B, Strobel E, Rawlins DB, Carson K, Zambrowicz B, Ding ZM.

Pharmacol Res Perspect. 2015 Mar;3(2):e00129. doi: 10.1002/prp2.129. Epub 2015 Mar 31.

11.

Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.

Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, Cole TB, DeVries PJ, Falls HD, Beam C, Gu J, Digiammarino EL, Palma JP, Donawho CK, Goodwin NC, Scott AM.

Mol Cancer Ther. 2015 May;14(5):1141-51. doi: 10.1158/1535-7163.MCT-14-0820. Epub 2015 Mar 2.

12.

Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.

Harrison BA, Almstead ZY, Burgoon H, Gardyan M, Goodwin NC, Healy J, Liu Y, Mabon R, Marinelli B, Samala L, Zhang Y, Stouch TR, Whitlock NA, Gopinathan S, McKnight B, Wang S, Patel N, Wilson AG, Hamman BD, Rice DS, Rawlins DB.

ACS Med Chem Lett. 2014 Nov 24;6(1):84-8. doi: 10.1021/ml500367g. eCollection 2015 Jan 8.

13.

Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.

Goodwin NC, Cianchetta G, Burgoon HA, Healy J, Mabon R, Strobel ED, Allen J, Wang S, Hamman BD, Rawlins DB.

ACS Med Chem Lett. 2014 Aug 7;6(1):53-7. doi: 10.1021/ml500242y. eCollection 2015 Jan 8.

14.

Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide.

Rodrigueza WV, Woolliscroft MJ, Ebrahim AS, Forgey R, McGovren PJ, Endert G, Wagner A, Holewa D, Aboukameel A, Gill RD, Bisgaier CL, Messmann RA, Whitehead CE, Izbicka E, Streeper R, Wick MC, Stiegler G, Stein CA, Monsma D, Webb C, Sooch MP, Panzner S, Mohammad R, Goodwin NC, Al-Katib A.

Cancer Chemother Pharmacol. 2014 Jul;74(1):151-66. doi: 10.1007/s00280-014-2476-y. Epub 2014 May 16.

15.

Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer.

Cooke DT, Gandara DR, Goodwin NC, Calhoun RF, Lara PN Jr, Mack PC, David EA.

J Thorac Cardiovasc Surg. 2014 Jul;148(1):36-40. doi: 10.1016/j.jtcvs.2014.03.014. Epub 2014 Mar 19.

16.

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

Zambrowicz B, Freiman J, Brown PM, Frazier KS, Turnage A, Bronner J, Ruff D, Shadoan M, Banks P, Mseeh F, Rawlins DB, Goodwin NC, Mabon R, Harrison BA, Wilson A, Sands A, Powell DR.

Clin Pharmacol Ther. 2012 Aug;92(2):158-69. doi: 10.1038/clpt.2012.58. Epub 2012 Jul 4.

17.

Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.

Goodwin NC, Mabon R, Harrison BA, Shadoan MK, Almstead ZY, Xie Y, Healy J, Buhring LM, DaCosta CM, Bardenhagen J, Mseeh F, Liu Q, Nouraldeen A, Wilson AG, Kimball SD, Powell DR, Rawlins DB.

J Med Chem. 2009 Oct 22;52(20):6201-4. doi: 10.1021/jm900951n.

PMID:
19785435
18.
19.

DelBank: a mouse ES-cell resource for generating deletions.

Goodwin NC, Ishida Y, Hartford S, Wnek C, Bergstrom RA, Leder P, Schimenti JC.

Nat Genet. 2001 Aug;28(4):310-1. No abstract available.

PMID:
11479588
20.

Mouse models for the Wolf-Hirschhorn deletion syndrome.

Näf D, Wilson LA, Bergstrom RA, Smith RS, Goodwin NC, Verkerk A, van Ommen GJ, Ackerman SL, Frankel WN, Schimenti JC.

Hum Mol Genet. 2001 Jan 15;10(2):91-8.

PMID:
11152656
21.

The B6.CE-Lyb-2c:Mup-1a mouse strain contains the interferon-alpha genes from C57BL/6.

Gollahon KA, Boyse EA, Goodwin NC, Greenfield BW.

Immunogenetics. 1992;35(1):62-4. No abstract available.

PMID:
1345906
22.

Blink coding for information display.

Smith SL, Goodwin NC.

Hum Factors. 1971 Jun;13(3):283-90. No abstract available.

PMID:
5558221
23.

Computer-generated speech and man-computer interaction.

Smith SL, Goodwin NC.

Hum Factors. 1970 Apr;12(2):215-23. No abstract available.

PMID:
5452056
24.

User input mode and computer-aided instruction.

Morrill CS, Goodwin NC, Smith SL.

Hum Factors. 1968 Jun;10(3):225-32. No abstract available.

PMID:
5674358

Supplemental Content

Loading ...
Support Center